Table 1 Summary of EAE incidence, onset, and maximum disease severity in different murine models of MS upon antibody mediated blocking of VLA-4, MCAM, or VLA-4 and MCAM
From: Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus
Mouse | Treatment | Incidence | Age (days)/day of onset | Cumulative score |
|---|---|---|---|---|
Integrin α4−/− | Anti-MCAM | 3/13 (23%) | 19.3 ± 0.66 | 0.21 ± 0.12 |
Integrin α4−/− | Isotype (MCAM) | 6/16 (38%) | 16.8 ± 0.65 | 0.38 ± 0.14 |
Devic | Anti-VLA-4 | 1/11 (9%) | 39 ± 0 | 0.01 ± 0.01 |
Devic | Isotype (VLA-4) | 7/11 (64%) | 33.7 ± 1.5 | 0.58 ± 0.16 |
Devic | Anti-MCAM | 9/22 (41%) | 34.3 ± 1.6 | 0.65 ± 0.19 |
Devic | Isotype (MCAM) | 12/21 (57%) | 36.1 ± 1.4 | 0.79 ± 0.19 |
Devic | Anti-VLA-4/MCAM | 2/11 (18%) | 35.5 ± 3.5 | 0.09 ± 0.07 |
Devic | Isotype (VLA-4/MCAM) | 9/11 (82%) | 30 ± 1.7 | 1.54 ± 0.09 |